Close
Biotechgate
| |

Home Page

Action required: Please refresh your browser

We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.

More details about this topic are available here »

Digital Transformation in the Pharmaceuticals Industry-Companies-to-Action, 2018 - Value-based Care, Patient Data Digitization, and Collaborative Technology Deployment Offer Investment Opportunities
By: PR Newswire Association LLC. - 21 Sep 2018Back to overview list

DUBLIN, Sept 21, 2018 /PRNewswire/ --

The "Digital Transformation in the Pharmaceuticals Industry-Companies-to-Action, 2018" report has been added to ResearchAndMarkets.com's offering.

The pharmaceutical industry today is in a state of flux as it tries to maintain a delicate balance between the need for novel blockbuster drugs and the need for improved operational efficiencies in an increasingly competitive market space. As healthcare is becoming increasingly democratized, patients are emerging as key decision makers-digitally enabled by the entry of non-traditional tech companies such as Apple, Facebook, and Google-pushing pharmaceutical companies to go beyond-the-pill.

However, in the midst of this chaos, there are pioneering companies offering solutions that apply cutting-edge digital technologies such as AI, Big Data and analytics, cloud, mobile, blockchain, and Internet of Things (IoT) to build digital convergence across the pharmaceutical value chain, covering R&D, manufacturing and operations, marketing, and patient connect. This Companies to Action (C2A) analysis puts the spotlight on such game-changing, tech-enabled participants and how they are altering the status-quo by highlighting novel monetization models and strategic investment opportunities.

Research Scope

The key objective of this study is to highlight current market dynamics, key market participants, customer segments, and evolving business opportunities. The study aims to identify pioneering companies that are capable of shaping the future through best practices implementation, visionary leadership, and innovation in business models. The company profiles offer insights around key solution offerings, target customer segments, service differentiators, and future growth strategies.

Further, the global study provides an analysis of companies segregated by market segments such as: smart R&D, flexible manufacturing, connected patients, and digital pharmacy. The analysis covers technologies such as Artificial intelligence (AI), Big Data and analytics, crowdsourcing, mobile, Industrial IoT (IIoT), IoT, cloud, blockchain, eCommerce, and so on.

The participants mentioned in the study are iSolve, Zephyr Health, PillPack, Proteus Digital Health, BenevolentAI, Elemental Machines, Exscientia, Science 37, Transparency Life Sciences, and uMotif. It also lists the wider universe of companies that were assessed for this analysis. These companies were chosen based factors such as innovative technology development and application, hitting the right focus areas, proven success and industry recognition, and enhanced client collaborations.


Key Issues Addressed

  • How are companies creating extraordinary value for pharmaceutical stakeholders?
  • Which are some unique companies that are introducing new and innovative solutions in the market?
  • How do these companies intend to transform the healthcare industry paradigms in the future? What is the impact of the external industry environment on this market?
  • What is their action plan and potential for growth? What are the current growth opportunities in digital transformation?
  • What are some key success factors in the pharmaceutical market?
  • Which are the companies with whom partnerships can be forged?

Key Topics Covered:

1. Executive Summary

  • Key Findings
  • Methodology
  • Scope and Segmentation
  • Key Questions this Study will Answer
  • Pillars of Digital Transformation and Growth Opportunity in Pharmaceuticals
  • Tackling Challenges in the Pharmaceuticals Industry
  • Major Challenges Limiting Digital Transformation

2. Companies-to-Action Overview

  • Companies-to-Action Value Creators
  • Threats and Opportunities
  • Strategic Imperatives for Digital Transformation in Pharmaceuticals

3. Market Overview

  • Definition and Solution Segmentation
  • Impact of Key Market Influencers
  • Pillars of Digital Transformation and Vendor Strategies
  • C2A Targets Aligned With Pillars of Digital Transformation

4. Companies-to-Action Profiles

  • Value Chain Analysis
  • Benchmarking of Top Companies-to-Action
  • BenevolentAI
  • Exscientia
  • Science 37
  • Transparency Life Science
  • Elemental Machines
  • iSolve
  • PillPack
  • Zephyr Health
  • Proteus Digital Health
  • uMotif

5. The Last Word

  • Building Life Science Digital Capabilities by Innovation Tracking
  • Conclusion-Key Takeaways From the Companies-to-Action Analysis
  • Legal Disclaimer

6. Appendix

  • List of Vendors Assessed
  • List of Exhibits

For more information about this report visit https://www.researchandmarkets.com/research/82blcx/digital?w=5

Did you know that we also offer Custom Research? Visit our Custom Research page to learn more and schedule a meeting with our Custom Research Manager.

Media Contact:


Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com   

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716 

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/digital-transformation-in-the-pharmaceuticals-industry-companies-to-action-2018---value-based-care-patient-data-digitization-and-collaborative-technology-deployment-offer-investment-opportunities-300716853.html

SOURCE Research and Markets

Copyright 2018 PR Newswire Association LLC. Back to overview list
to the top ↑